{"id":"NCT05637515","sponsor":"Biocon Biologics Inc.","briefTitle":"Hulio Interchangeability to Humira®, Comparing Pharmacokinetics, Efficacy, Safety and Immunogenicity","officialTitle":"A Multicenter, Randomized, Blinded, Parallel Group, Interchangeability Study in Moderate to Severe Chronic Plaque Psoriasis Evaluating Pharmacokinetics, Efficacy, Safety, and Immunogenicity Between Subjects Receiving Humira® Pre Filled Syringe (40 mg) Continuously and Subjects Undergoing Repeated Switches Between Humira® Pre Filled Syringe (40 mg) and Hulio Pre-filled Syringe (40 mg)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-11-21","primaryCompletion":"2023-09-19","completion":"2023-09-19","firstPosted":"2022-12-05","resultsPosted":"2024-10-15","lastUpdate":"2024-10-22"},"enrollment":374,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate Chronic Plaque Psoriasis","Severe Chronic Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Humira 40 MG in Prefilled Syringe","otherNames":[]},{"type":"BIOLOGICAL","name":"Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled Syringe","otherNames":[]}],"arms":[{"label":"Humira continuously","type":"ACTIVE_COMPARATOR"},{"label":"Repeated switches Humira - Hulio","type":"EXPERIMENTAL"}],"summary":"Hulio is a monoclonal antibody currently approved as a biosimilar to European Union approved and United States (US)-Licensed Humira.\n\nThis is a multicenter, randomized blinded, parallel group, interchangeability study in subjects with moderate to severe chronic plaque psoriasis, undergoing repeated switches between Humira and Hulio. The study is designed to confirm the pharmacokinetic equivalence of alternating between the use of Humira and Hulio and, Humira without such alternation or switch, in accordance with the US Food and Drug Administration Guidance for Industry, Considerations in Demonstrating Interchangeability with a Reference Product.\n\nThe study will also assess safety, efficacy and immunogenicity between these two groups.","primaryOutcome":{"measure":"Primary Endpoints: Pharmacokinetics (PK) - AUC","timeFrame":"Week 26 - 28","effectByArm":[{"arm":"Group 1 :- Humira Continuously","deltaMin":2127.57,"sd":1432.8},{"arm":"Group 2:- Repeated Switches Humira - Hulio","deltaMin":2357.61,"sd":1636.09}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["Bulgaria","Czechia","Estonia","Poland"]},"refs":{"pmids":["40493334"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":193},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Alanine aminotransferase increased","Pharyngitis"]}}